A049180 Stock Overview
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Cellumed Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩1,792.00 |
52 Week High | ₩7,300.00 |
52 Week Low | ₩1,600.00 |
Beta | 0.58 |
1 Month Change | -6.72% |
3 Month Change | -16.65% |
1 Year Change | -67.65% |
3 Year Change | -72.85% |
5 Year Change | -80.77% |
Change since IPO | -83.01% |
Recent News & Updates
Recent updates
Shareholder Returns
A049180 | KR Medical Equipment | KR Market | |
---|---|---|---|
7D | 6.4% | 8.9% | 3.8% |
1Y | -67.7% | 45.3% | 13.0% |
Return vs Industry: A049180 underperformed the KR Medical Equipment industry which returned 45.3% over the past year.
Return vs Market: A049180 underperformed the KR Market which returned 13% over the past year.
Price Volatility
A049180 volatility | |
---|---|
A049180 Average Weekly Movement | 10.9% |
Medical Equipment Industry Average Movement | 6.6% |
Market Average Movement | 5.3% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A049180's share price has been volatile over the past 3 months.
Volatility Over Time: A049180's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 103 | In-soo Yoo | https://www.cellumed.co.kr |
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones.
Cellumed Co.,Ltd. Fundamentals Summary
A049180 fundamental statistics | |
---|---|
Market cap | ₩76.69b |
Earnings (TTM) | -₩20.08b |
Revenue (TTM) | ₩95.47b |
0.8x
P/S Ratio-3.8x
P/E RatioIs A049180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A049180 income statement (TTM) | |
---|---|
Revenue | ₩95.47b |
Cost of Revenue | ₩90.51b |
Gross Profit | ₩4.96b |
Other Expenses | ₩25.04b |
Earnings | -₩20.08b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -469.24 |
Gross Margin | 5.19% |
Net Profit Margin | -21.03% |
Debt/Equity Ratio | 25.9% |
How did A049180 perform over the long term?
See historical performance and comparison